Michael Savona is a Hematology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 The Vanderbilt Clini
Nashville, TN 372325100
Telephone
615-322-3000Provider last certified this registry record 14 Oct 2024.
Clinical trials
- Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients
Sponsor: National Cancer Institute (NCI)
- Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis
Sponsor: Incyte Corporation
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Geron CorporationProgram year20257 payments$12,931openpaymentsdata.cms.gov ↗
- PharmaEssentia USA CorporationProgram year20252 payments
- Janssen Research & Development, LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
86.3%Kinase inhibitor72.7%Jakafi100%Part D≥22 patientsJanus-associated kinase (JAK) inhibitors7%Ojjaara100%Part D<11 patients+ 1 more class in this area
Musculoskeletal
8.8%Xanthine oxidase inhibitor8.8%Allopurinol100%Part D<11 patientsAnti-infectives
4.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor4.8%Valacyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Development of a Phenotype-based Predictive Analytic for Acute Myeloid Leukemia
Vanderbilt University Medical Center
FY2026$680,660R01CA262287 - F1 inhibition of OXPHOS to ameliorate hyperproliferative erythropoiesis
Vanderbilt University Medical Center
FY2026$449,505R21CA318444 - Single Cell Foundation Model enabled drug discovery for clonal hematopoiesis
Vanderbilt University Medical Center
FY2025$1,013,072UG3AG097155
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Tait Shanafelt, MD
Palo Alto University
Robert Bast, MD
The University of Texas MD Anderson Cancer Center
Thomas Witzig, MD
Mayo Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”